It is expected to see Korean Companies to Have Solid Competitiveness on Development of Biosimilar Antibodies

While development of Biosimilar antibodies, a generic drug of the original biomedicine, is getting intensified, the Korean companies are expected to have solid competitiveness. 

According to the data about the current development of Biosimilar antibodies, given by Hyun-Tae Kim, KDB Daewoo Finance Analyst, multiple Korean companies are competing for the development of global Big Pharma and Bios...